1019 ET - Hims & Hers Health is still benefiting from the fact that consumers are struggling to obtain branded weight-loss drugs, known as GLP-1s, TD Cowen analysts say in a research note. The stock has been volatile due to uncertainty around whether Hims can keep offering its compounded GLP-1 after a shortage of branded GLP-1s was resolved, the analysts say. But the environment for GLP-1s is still highly dynamic and Hims' compounded version is still a credible solution for consumers that can't easily get branded GLP-1s, the analysts say. That said, the risk remains that regulators could swoop in at some point with new restrictions around compounded drugs, the analysts say. (dean.seal@wsj.com)
(END) Dow Jones Newswires
November 05, 2024 10:19 ET (15:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。